Teachers Retirement System of The State of Kentucky cut its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,448 shares of the company's stock after selling 836,539 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Ginkgo Bioworks were worth $175,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Pine Valley Investments Ltd Liability Co boosted its holdings in Ginkgo Bioworks by 653.7% in the 2nd quarter. Pine Valley Investments Ltd Liability Co now owns 220,607 shares of the company's stock worth $74,000 after buying an additional 191,336 shares during the period. North Star Asset Management Inc. grew its position in shares of Ginkgo Bioworks by 162.6% during the 2nd quarter. North Star Asset Management Inc. now owns 231,100 shares of the company's stock valued at $77,000 after purchasing an additional 143,100 shares in the last quarter. Monaco Asset Management SAM bought a new position in shares of Ginkgo Bioworks in the second quarter worth $3,276,000. Thoroughbred Financial Services LLC purchased a new stake in shares of Ginkgo Bioworks in the second quarter worth $70,000. Finally, Renaissance Technologies LLC bought a new stake in Ginkgo Bioworks during the second quarter valued at $2,128,000. Hedge funds and other institutional investors own 78.63% of the company's stock.
A number of equities analysts have weighed in on DNA shares. BTIG Research upped their target price on Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a research note on Friday, August 23rd. TD Cowen raised their target price on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, September 20th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $4.58.
View Our Latest Stock Analysis on Ginkgo Bioworks
Shares of DNA stock opened at $8.74 on Friday. The company has a market capitalization of $502.37 million, a price-to-earnings ratio of -0.67 and a beta of 1.17. The business's 50-day moving average price is $8.50. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.26 and a 12-month high of $75.20.
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.